Skip to main content

Table 6 Pattern of change in PROs among dual and triple users prior, during and at the end of treatment

From: Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt

Variables/Time

Triple therapy N = 26

Dual therapy N = 10

Mean + SD

Chi-Square

P-value

Mean + SD

Chi-Square

P-value

HRQoL

 

 T0

29.81 ± 15.87

10.26

.006

34.20 ± 13.98

.47

.79

 T1

43.35 ± 21.15

30.00 ± 18.63

 T2

37.54 ± 20.47

26.60 ± 17.02

Symptom experience

 

 Symptom severity

 

  T0

22.69 ± 10.29

8.00

.01

24.50 ± 10.46

.68

.71

  T1

29.77 ± 12.31

21.10 ± 13.54

  T2

26.58 ± 12.29

18.20 ± 12.51

 Symptom hindrance

 

  T0

7.12 ± 6.67

13.01

.001

9.70 ± 5.54

.15

.92

  T1

13.58 ± 9.66

8.90 ± 6.23

  T2

10.96 ± 8.72

8.40 ± 5.10

Mental Health

 

 Depression

 

  T0

8.58 ± 6.65

11.40

.003

9.80 ± 8.99

5.70

.05

  T1

10.62 ± 6.93

11.20 ± 8.18

  T2

10.04 ± 6.40

6.20 ± 6.49

 Anxiety

 

  T0

7.69 ± 6.04

4.95

.08

6.40 ± 5.29

2.10

.34

  T1

9.62 ± 5.97

7.00 ± 5.46

  T2

7.77 ± 6.62

4.50 ± 3.54

 Stress

 

  T0

11.54 ± 7.27

4.93

.08

9.40 ± 7.72

.70

.70

  T1

12.92 ± 6.63

9.80 ± 7.19

  T2

11.04 ± 6.99

6.40 ± 5.17

 MSPSS

 

  T0

2.45 ± .40

6.65

.03

2.31 ± .64

6.58

.03

  T1

2.54 ± .35

2.43 ± .44

  T2

2.42 ± .40

2.41 ± .41

  1. HRQoL health-related quality of life, T0 time 0, T1time 1, T2time 2, MSPSS Multidimensional Scale of Perceived Social Support
  2. P value significant at two tailed
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us